Patient enrolment

The MASTER DAPT trial started operations on October 3^rd, 2016 with first Ethics Approval achieved after 2.5 months at the Research and Ethics Committee King Fahd Armed Forces Hospital Jeddah Saudi-Arabia. All participating sites were active after 34 months from start of activities.

The MASTER DAPT trial included 140 sites in 30 countries. Sites were distributed as follows:

Country	Sites
FR	16
NL	11
CH	7
BE	6
GB	12
IT	16
EE	1
ES	10
JP	13
BG	4
PL	5
IN	4
AU	5
RS	3
CZ	2
MK	1
IL	4
HU	2
SG	2
AT	2
BD	1
VN	1
DE	2
AR	3
SA	1
KR	1
DK	1
SE	2
BH	1
PT	1

The first patient was enrolled on 04/04/2017 at Scheper Ziekenhuis, Emmen, the Netherlands with Dr. G. Jessurun being the site Principal Investigator. Enrolment of all participants, amounting to 4578 was achieved on December 10^th, 2019 at Policlinico Casilino, Rome, Italy with Dr. M. Donahue being the site Principal Investigator. The achieved rate of enrolment was 1.0 patient/site/month.

Enrolment per country was distributed as follows:

Country	Total randomized
FR	576
NL	539
CH	499
BE	301
GB	279
IT	276
EE	259
ES	196
JP	187
BG	183
PL	177
IN	148
AU	142
RS	138
CZ	134
MK	120
IL	100
HU	68
SG	47
AT	44
BD	39
VN	25
DE	25
AR	16
SA	16
KR	15
DK	13
SE	8
BH	7
PT	1

The top 3 enrolling sites in the MASTER DAPT were:

1. Inselspital, Bern, Zwitserland, Dr. A. Moschovitis (308 patients)
2. North-Estonia Medical Centre, Tallinn, Estonia, Dr. P. Laanmets (259 patients)
3. Maasstad hospital, Rotterdam, the Netherlands, Dr. P. Smits (233 patients)

The MASTER DAPT achieved complete follow-up on Q1 2021, and results are expected on Q3 2021.